PDCD1 and neoplasm: Anyway, in the preclinical studies the pharmacological antagonism of CD39/CD73—adenosine signaling potentiated anti-tumor responses in preclinical models that otherwise failed to respond to anti-PD-1/PD-L1 inhibition.